Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mint nicotine gum approved

This article was originally published in The Tan Sheet

Executive Summary

FDA approves Dec. 29 Corona, Calif.-based Watson Laboratories' mint-flavored OTC Nicotine Polacrilex gum in 2 mg and 4 mg. The gum is the generic equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette fresh mint gum, and will hit store shelves in early January. More than $300 million of nicotine gum was sold in the 12 months ending September 2008, according to Information Resources Inc. sales data

You may also be interested in...

FDA okays Watson's flavored nicotine gum

FDA approves Morristown, N.J.-based Watson Laboratories' sale of 2 mg and 4 mg nicotine polacrilex gum coated with fruit and cinnamon flavors. The name brand equivalent Nicorette Fruit Chill and Cinnamon Sugar Coated Gums helped GlaxoSmithKline sell more than $305 million of the gum in the 12 months ending March 29, Watson says in a July 8 release. FDA approved Watson's mint-flavored equivalent of GlaxoSmithKline Consumer Healthcare's Nicorette gum in December 2008 (1"The Tan Sheet" Jan. 5, 2009, In Brief)

The Good, The Bad And The Ugly Of COVID-19 Vaccine Manufacturing Technology Platforms

Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.

SparingVision Raises €44.5m For Mutation-Agnostic Eye Gene Therapy

A long-term, patient-centric group of investors is backing SparingVision's bid to develop a gene therapy treatment for retinitis pigmentosa that could be effective regardless of mutation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts